Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Harvard Business School
Baxter
Dow
Johnson and Johnson

Last Updated: December 16, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for ASLAN001

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug ASLAN001?

ASLAN001 is an investigational drug.

There have been 11 clinical trials for ASLAN001. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2017.

The most common disease conditions in clinical trials are Biliary Tract Neoplasms, Stomach Neoplasms, and Carcinoma, Hepatocellular. The leading clinical trial sponsors are Aslan Pharmaceuticals, National University Hospital, Singapore, and National Cancer Centre, Singapore.

There are two US patents protecting this investigational drug and seven international patents.

Recent Clinical Trials for ASLAN001
TitleSponsorPhase
Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract CancerAslan PharmaceuticalsPhase 2
Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line)Aslan PharmaceuticalsPhase 2/Phase 3
Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract CancerAslan PharmaceuticalsPhase 2/Phase 3

See all ASLAN001 clinical trials

Clinical Trial Summary for ASLAN001

Top disease conditions for ASLAN001
Top clinical trial sponsors for ASLAN001

See all ASLAN001 clinical trials

US Patents for ASLAN001

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
ASLAN001   Start Trial Methods for the treatment of HER2 amplified cancer Pharmacyclics LLC (Sunnyvale, CA)   Start Trial
ASLAN001   Start Trial Methods for the treatment of HER2 amplified cancer Pharmacyclics LLC (Sunnyvale, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for ASLAN001

Drugname Country Document Number Estimated Expiration Related US Patent
ASLAN001 Canada 2920534 2033-08-12   Start Trial
ASLAN001 European Patent Office 3033079 2033-08-12   Start Trial
ASLAN001 Spain 2709509 2033-08-12   Start Trial
ASLAN001 Japan 2016528251 2033-08-12   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Medtronic
Moodys
AstraZeneca
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.